Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
CVS Caremark
CVS Caremark Applauds FTC's Leadership on Follow-on Biologics
December 13th, 2008
CVS Caremark today applauded the Federal Trade Commission (FTC) for holding a public Roundtable to address issues of competition and continued innovation under a framework for follow-on biologic drugs. "CVS Caremark serves millions of patients, many of whom depend on specialty drugs to provide life-saving and life-enhancing treatments for their serious conditions. We support the creation of a federal legislative pathway for FDA approval of these medicines to provide access and savings to patients and payors," said Dave Golding, R.Ph., Executive Vice President for Specialty Pharmacy services at CVS Caremark. "Increased competition in the biologics market will benefit...
Source: Law & Health Weekly (2008-12-13)
|
